Abstract
Purpose :
To evaluate the clinical and imaging features as well as treatment offered to patients with Leaky Choroidal Nevi and their outcome.
Methods :
The charts of patients with a choroidal nevus crossing the temporal arcades inwards and showing leakage on OCT were reviewed. We analyzed the clinical features, findings on ancillary tests (OCT, Color Fundus Picture, Fluorescein Angiography and Eye Ultrasound) and treatment methods used.
Results :
Throughout the review of almost 12 years, 17 patients with the above diagnosis presented loss of at least one logMAR line in 57.14% of the cases; improvement in 28.57%, and stability in 14.29%. By Posterior Segment US, an increase of both mean tumor thickness and largest base was of 0.8mm. SRF was the most common finding on OCT. All lesions that required treatment received intravitreal Bevacizumab, with a mean number of injections of 5.41. 25% of these patients presented VA improvement. Although PDT was reserved as a 2-4 line of treatment, 3 out of 4 patients treated with this modality had an anatomical improvement and 1 out of 4 with a functional improvement. Intravitreal Ranibizumab, Focal LASER and TTT were also used.
Conclusions :
Leaky Choroidal Nevi is a term proposed for borderline, suspicious lesions with deleterious effects on visual acuity. A short trial of Bevacizumab can be warranted initially and consolidated by PDT if needed. Close follow-up is suggested due to its morbidity and the risk of conversion to Choroidal Melanoma.
This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.